Prevalence,Knowledge and Attitude of HIV /AIDS in Luxor
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03485599 |
|
Recruitment Status : Unknown
Verified March 2018 by Zienab Gamea, Assiut University.
Recruitment status was: Not yet recruiting
First Posted : April 2, 2018
Last Update Posted : April 2, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Human immunodeficiency virus infection is a global pandemic problem. About 35.3 million infected people in the world, so causing a great social, economical, political and cultural problems worldwide.
In 1986 Egypt's first AIDS case was discovered , since then the number of infected cases cases are increasing.According to United Nations 2016 statistics, there are about 11,000 infected people living with Human immunodeficiency virus in Egypt.
| Condition or disease | Intervention/treatment |
|---|---|
| HIV/AIDS | Diagnostic Test: ELIZA , Westron blot |
Human immunodeficiency virus is a lentivirus that causes the infection and over time leading to Acquired immunodeficiency syndrome.
The virus spread primarily by unprotected sex including vaginal, anal and oral sex, contaminated blood transfusions, infected needles, and from mother to child during pregnancy, delivery, or from milk during breastfeeding.
In 1986 Egypt's first AIDS case was discovered , since then the number of infected cases cases are increasing.According to United Nations 2016 statistics, there are about 11,000 infected people living with Human immunodeficiency virus in Egypt.
According to the National Aids Program, the primary mode of transmission is heterosexual intercourse, followed by homosexual intercourse , renal dialysis , and blood transfusion Others include street children, prisoners, and refugees, female sex workers, men have sex with men, and injecting drug users.
Human immunodeficiency virus related stigma and discrimination is a great barrier to effectively fighting the disease epidemic.
This study will assess prevalence, knowledge, attitudes of Human immunodeficiency virus and Acquired immunodeficiency syndrome people in Luxor Governorate in Upper Egypt.
| Study Type : | Observational |
| Estimated Enrollment : | 400 participants |
| Observational Model: | Ecologic or Community |
| Time Perspective: | Cross-Sectional |
| Official Title: | Prevalence,Knowledge and Attitude of HIV /AIDS in Luxor |
| Estimated Study Start Date : | January 2019 |
| Estimated Primary Completion Date : | December 2019 |
| Estimated Study Completion Date : | April 2020 |
| Group/Cohort | Intervention/treatment |
|---|---|
|
HIV infected people
Blood samples will be taken and rapid HIV test by ELIZA will be done ,for positive cases Westron blot done
|
Diagnostic Test: ELIZA , Westron blot
Blood sample will be taken then rapid test by ELIZA will be done if positive then confirmatory test by Westron blot will be done |
- knowledge score [ Time Frame: 20 mintues ]Questionnaire to define knowledge score of HIV/AIDS through an interview
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | Child, Adult, Older Adult |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
1-People living in Luxor. 2 Subjects of high risk groups as men have sex with men, children street, female sex workers.
3-People clinically diagnosed as HIV/AIDS. 4-People in contact with HIV/AIDS patients.
Exclusion Criteria:
1 - Subjects outside Luxor 2- People refused to consent 3- Mentally disordered patients
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03485599
| Contact: Hisham Zayan, Assistant | 01223971409 | hishamzayan@icloud.com | |
| Contact: Yasmine Mostafa, Lecturer | 01006033331 | dr.yasminemostawfik@yahoo.com |
| Egypt | |
| Faculty of Medicine | |
| Assiut, Egypt, 71111 | |
| Contact: Amira El Gazar, lecturer 01008194433 Elgazzar44@yahoo.com | |
| Study Director: | Hisham Zayan, Assistant | Assiut University |
| Responsible Party: | Zienab Gamea, Principal Investigator, Assiut University |
| ClinicalTrials.gov Identifier: | NCT03485599 |
| Other Study ID Numbers: |
PKHIVL |
| First Posted: | April 2, 2018 Key Record Dates |
| Last Update Posted: | April 2, 2018 |
| Last Verified: | March 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Acquired Immunodeficiency Syndrome HIV Infections Blood-Borne Infections Communicable Diseases Infections Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases |
Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Slow Virus Diseases Immunologic Deficiency Syndromes Immune System Diseases |

